Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits
Dermatology Practical & Conceptual · 31.07.2025 · 15 (3) · 5845
DOI: 10.5826/dpc.1503a5845 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatology Practical & Conceptual, online erschienen am 31.07.2025. Verfasst von Edoardo Cammarata und 20 weiteren Autor:innen. Beteiligte Einrichtung: SCDU Dermatologia, AOU Maggiore della Carità, Novara, Italy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Introduction
Psoriasis is a chronic inflammatory multisystem disease for which IL-17 and IL-23 inhibitors have transformed treatment. However, high costs, and the possibility of overtreatment in patients with excellent and sustained responses have driven interest in dose-reduction (DR) to lower expenses without compromising efficacy. Materials & Methods: We conducted an observational multicentric trial assessing the efficacy and safety of DRs for secukinumab, brodalumab, guselkumab, and risankizumab in adults with stable plaque psoriasis. Eligible participants were adults with low disease activity (PASI ≤ 3, DLQI ≤ 3 for at least 9 months). DR involved lengthening intervals to approximately 67% of the authorized standard dose. From the 361 enrolled (March 2023–January 2025), we analyzed data on 156 participants with ≥12 months of follow-up or early discontinuation due to DR failure.
Results
Seventy of these patients (44.87%) received IL-17 inhibitors, and 86 (55.13%) received IL-23 inhibitors. After 52 weeks, the overall dose-reduction survival was 0.75 [95% CI 0.69; 0.82]. In particular, for IL-23 inhibitors and IL17 inhibitors cohorts, the dose-reduction survival was 0.83 [95%CI 0.75; 0.91] and 0.66 [95%CI 0.55; 0.78] respectively. Moreover, Kaplan-Meier curves suggested significant (p-value log-rank test=0.018) higher dose reduction survival for IL-23 inhibitors compared to IL-17.
Discussion
Our preliminary findings suggest that extended dosing intervals for IL-17 and IL-23 inhibitors can effectively maintain disease control in stable plaque psoriasis. Larger, randomized trials are needed to confirm these results, identify predictive markers of DR success, and optimize patient selection for safe and cost-effective management of psoriasis.
Autor:innen und Institutionen
- SCDU Dermatologia, AOU Maggiore della Carità, Novara, Italy.
- Dept of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
- Hospital Pharmacy, AOU Maggiore della Carità, Novara, Italy.
- Dermatologic Clinic, Department of Clinical Medicine, University of Turin, Turin, Italy.
- SSD Dermatologia, AO Santa Croce e Carle Hospital, Cuneo, Italy.
- SS Dermatologia, AOU SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Zitieren
APA
Cammarata, E., Airoldi, C., Colombo, J., Ucciero, A., Mastorino, L., Arese, V., Burzi, L., Castelli, F., Chiarpenello, M., Graziola, F., Leporati, C., Ortoncelli, M., Pella, P., Pertusi, G., Pisterna, A., Quaglino, P., Ribero, S., Rossotto, G., Tiberio, R., …, & Savoia, P. (2025). Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits. Dermatology Practical & Conceptual, 15(3), 5845. https://doi.org/10.5826/dpc.1503a5845
Vancouver
Cammarata E, Airoldi C, Colombo J, Ucciero A, Mastorino L, Arese V, et al. Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits. Dermatology Practical & Conceptual. 2025;15(3):5845. doi:10.5826/dpc.1503a5845
BibTeX
@article{Cammarata2025,
author = {Cammarata, Edoardo and Airoldi, Chiara and Colombo, Jacopo and Ucciero, Andrealuna and Mastorino, Luca and Arese, Veronica and Burzi, Lorenza and Castelli, Franco and Chiarpenello, Massimo and Graziola, Francesca and Leporati, Claudia and Ortoncelli, Michela and Pella, Paolo and Pertusi, Ginevra and Pisterna, Alessia and Quaglino, Pietro and Ribero, Simone and Rossotto, Gianluca and Tiberio, Rossana and Dapavo, Paolo and Savoia, Paola},
title = {Impact of Disease Activity-Guided Dose Reduction on IL-17 and IL-23 Inhibitors in Psoriasis: A Real-World Assessment of Efficacy, Safety, and Economic Benefits},
journal = {Dermatology Practical & Conceptual},
year = {2025},
volume = {15},
number = {3},
pages = {5845},
doi = {10.5826/dpc.1503a5845}
}
EUVIMED